title: Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation.
abstract: Outcomes and prognostic factors of reduced intensity-conditioned allo-SCT (RIC allo-SCT) for multiple myeloma (MM) relapsing or progressing after prior autologous (auto)-SCT are not well defined. We performed an analysis of 413 MM patients who received a related or unrelated RIC allo-SCT for the treatment of relapse/progression after prior auto-SCT. Median age at RIC allo-SCT was 54.1 years, and 44.6% of patients had undergone two or more prior auto-SCTs. Median OS and PFS from the time of RIC allo-SCT for the entire population were 24.7 and 9.6 months, respectively. Cumulative non-relapse mortality (NRM) at 1 year was 21.5%. In multivariate analysis, CMV seronegativity of both patient and donor was associated with significantly better PFS, OS and NRM. Patient-donor gender mismatch was associated with better PFS, fewer than two prior auto-SCT was associated with better OS, and shorter time from the first auto-SCT to the RIC allo-SCT was associated with lower NRM. The results of this study identify patient and donor CMV seronegativity as the key prognostic factor for outcome after RIC allo-SCT for MM relapsing or progressing after prior auto-SCT.
authors.affiliation: Department of Medicine, Centre for Haematology, Hammersmith Hospital Campus, Imperial College London, London, UK.
authors.forename: H W
authors.initials: HW
authors.lastname: Auner
authors.forename: R
authors.initials: R
authors.lastname: Szydlo
authors.forename: A
authors.initials: A
authors.lastname: van Biezen
authors.forename: S
authors.initials: S
authors.lastname: Iacobelli
authors.forename: G
authors.initials: G
authors.lastname: Gahrton
authors.forename: N
authors.initials: N
authors.lastname: Milpied
authors.forename: L
authors.initials: L
authors.lastname: Volin
authors.forename: J
authors.initials: J
authors.lastname: Janssen
authors.forename: S
authors.initials: S
authors.lastname: Nguyen Quoc
authors.forename: M
authors.initials: M
authors.lastname: Michallet
authors.forename: H
authors.initials: H
authors.lastname: Schoemans
authors.forename: J
authors.initials: J
authors.lastname: El Cheikh
authors.forename: E
authors.initials: E
authors.lastname: Petersen
authors.forename: F
authors.initials: F
authors.lastname: Guilhot
authors.forename: S
authors.initials: S
authors.lastname: Schönland
authors.forename: L
authors.initials: L
authors.lastname: Ahlberg
authors.forename: C
authors.initials: C
authors.lastname: Morris
authors.forename: L
authors.initials: L
authors.lastname: Garderet
authors.forename: T
authors.initials: T
authors.lastname: de Witte
authors.forename: N
authors.initials: N
authors.lastname: Kröger
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000601:surgery / Q000628:therapy*; D011379:Prognosis; D012008:Recurrence; D016896:Treatment Outcome; D055815:Young Adult